Clinical-stage nuclear medicine company Radiopharm Theranostics (ASX:RAD) has announced the publication of positive results of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients.

Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.

Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

AusBiotech has announced the creation of the Depaz Oration, an annual keynote to be introduced at its national conference in 2025 in memory of the late Dr Iris Depaz.

Amplia Therapeutics (ASX:ATX) has announced that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio.

AVITA Medical (ASX:AVH) has announced it has entered into an exclusive distribution agreement with Revolution Surgical to expand into the Australian and New Zealand markets.

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that Ascent Health, the second largest Payer organisation in the US, will cover Sofdra (sofpironium) topical gel, 12.45 per cent.

The company said the funds will support the ongoing commercialisation of its AI platform that detects critical coronary artery disease imaging markers.

Medical data and technology company HeraMED (ASX:HMD) has received and accepted a further investment offer via a private placement of $1.02 million from three institutional investors.

EMVision Medical Devices (ASX:EMV) has announced positive results for its neurodiagnostic technology to identify stroke and stroke types.

Researchers at Monash University have developed a light-emitting microchip that can measure the energy produced by embryos, a key indicator of embryo health.

AusBiotech and MTPConnect have released a discussion paper ahead of their upcoming National Biotech and Medtech Development and Commercialisation Summit on 19 November 2024 in Canberra.

PYC Therapeutics (ASX:PYC) has announced that the first patient with Autosomal Dominant Optic Atrophy (ADOA) has received their first dose of PYC-001.

Recce Pharmaceuticals (ASX:RCE) says it is nearing completion of its Phase 2 clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections.

Optiscan Imaging (ASX:OIL) has signed an agreement with Monash University to help the company advance its project to develop the next-gen gastrointestinal (GI) flexible endomicroscope and Edge-AI-enabled technology.

Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. 

Australia’s biotechnology industry has gathered in record numbers at the annual AusBiotech conference, held in Melbourne this week.